Healthcare Utilization and Costs of Care in Patients With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation After Initiating Oral Therapies: Real-World Analysis in the US Medicare Population
These findings suggest that linaclotide treatment may be associated with lower total healthcare costs compared to lubiprostone and plecanatide for patients initiating IBS-C/CIC-related drugs in Medicare populations.
Authors
- Mena Boules (ORCID: https://orcid.org/0000-0002-5962-9271)
- Eric D. Shah (ORCID: https://orcid.org/0000-0003-3611-8628)
- Zachary K. Baldwin
- Yuri Sánchez González (ORCID: https://orcid.org/0000-0001-7261-1933)
- Steven Champaloux
- Tsung‐Ying Lee (ORCID: https://orcid.org/0000-0003-0633-3140)
- Jens J. Kort
- Masakazu Ando
Institutions
- Ironwood Pharmaceuticals (United States) (US)
- University of Michigan (US)
- AbbVie (United States) (US)
Publication Details
- Journal
- Advances in Therapy
- Published
- 2025-03-28
- DOI
- https://doi.org/10.1007/s12325-025-03163-1
- Citations
- 1
- Primary Topic
- Gastrointestinal motility and disorders
- Type
- article
- Field-Weighted Citation Impact
- 1.81
Funders
- AbbVie